Celcuity Inc. (NASDAQ:CELC) Receives $28.67 Consensus Target Price from Brokerages

Celcuity Inc. (NASDAQ:CELC) has earned an average rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $28.67.

A number of brokerages have recently weighed in on CELC. Lifesci Capital initiated coverage on shares of Celcuity in a report on Monday, August 26th. They set an “outperform” rating and a $27.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Celcuity in a report on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partners began coverage on Celcuity in a research report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective for the company. Finally, Stifel Nicolaus decreased their target price on Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th.

Celcuity Price Performance

Celcuity stock opened at $14.98 on Wednesday. The firm has a market cap of $554.71 million, a PE ratio of -5.39 and a beta of 0.76. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95. The stock’s fifty day moving average price is $16.87 and its two-hundred day moving average price is $16.96. Celcuity has a one year low of $8.39 and a one year high of $22.19.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. During the same period in the prior year, the firm posted ($0.66) earnings per share. As a group, research analysts expect that Celcuity will post -2.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CELC. Perceptive Advisors LLC acquired a new stake in Celcuity in the fourth quarter valued at $21,583,000. Baker BROS. Advisors LP grew its position in shares of Celcuity by 189.9% in the 1st quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after buying an additional 1,017,000 shares during the last quarter. Samlyn Capital LLC grew its position in shares of Celcuity by 92.4% in the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after buying an additional 637,190 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Celcuity in the first quarter valued at about $3,545,000. Finally, Driehaus Capital Management LLC raised its position in shares of Celcuity by 62.3% during the second quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock worth $3,351,000 after acquiring an additional 78,525 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.